Monday, 26 Aug 2019

You are here

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Researchers from Reed National Military Medical Center studied a systemic sclerosis (SSc) cohort seen between 2005 and 2016, specifically looking at 31 cases of newly diagnosed SSc cases who developed SRC after SSc diagnosis (compared to 322 without SRC).

The following findings at SSc diagnosis were predictive of future SRC:

  • proteinuria (p < 0.001; OR 183, 95% CI 19.1–1750),
  • anemia (p = 0.001; OR 9.9, 95% CI 2.7–36.2),
  • hypertension (p < 0.001; OR 13.1, 95% CI 4.7–36.6),
  • chronic kidney disease (p = 0.008; OR 20.7, 95% CI 2.2–190.7),
  • elevated erythrocyte sedimentation rate (p < 0.001; OR 14.3, 95% CI 4.8–43.0),
  • thrombocytopenia (p = 0.03; OR 7.0, 95% CI 1.2–42.7),
  • hypothyroidism (p = 0.01; OR 2.8, 95% CI 1.2–6.7),
  • anti-Ro antibody seropositivity (p = 0.003; OR 3.9, 95% CI 1.6–9.8), and
  • anti-RNA polymerase III antibodies (p = 0.02; OR 4.1, 95% CI 1.2–13.8).

Individually the predictive value for SRC was low, but finding any three or more of these present at diagnosis was sensitive (77%) and specific (97%) for future SRC. No SSc without SRC disease controls had ≥ 4 risk factors.

These profiles add to the current list and should be considered in new SSc patients as they may benefit from close observation of blood pressure, proteinuria, and other signs of renal crisis. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.